Latest Heparin Stories
SILVER SPRING, Md., July 23 /PRNewswire-USNewswire/ -- The U.S.
BETHLEHEM, Pa., July 12 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun) announced today the availability of large volume heparin infusion solutions.
An ultra-low-molecular-weight heparin called semuloparin has been found to reduce the incidence of venous thromboembolism in orthopedic surgery patients in a large clinical program being lead by a steering committee chaired by McMaster University professor Dr. Alexander Turpie.
SCHAUMBURG, Ill., July 1 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's nine presentations of heparin sodium injection, USP.
In research led by a Saint Louis University investigator, molecular biologists have discovered a way to harness the enzyme thrombin's anti-blood clotting properties.
ST. LOUIS, June 18 /PRNewswire-USNewswire/ -- In research led by a Saint Louis University investigator, molecular biologists have discovered a way to harness the enzyme thrombin's anti-blood clotting properties.
SUNNYVALE, Calif., June 14 /PRNewswire/ -- Cardiva Medical, Inc. announced today that Charles Maroney has been appointed President, Chief Executive Officer and member of the Cardiva Board of Directors effective immediately. Mr.
New treatments for malaria are possible after Walter and Eliza Hall Institute scientists found that molecules similar to the blood-thinning drug heparin can stop malaria from infecting red blood cells.
PHILADELPHIA, May 25 /PRNewswire/ -- Lyophilized heparin, a proprietary anticoagulant developed specifically for cord blood collection, demonstrated a better ability to preserve the number of viable cells over a longer period of time than a commonly-used anticoagulant, citrate phosphate dextrose (CPD), according to a study presented today at the International Society for Cellular Therapy (ISCT) Annual Meeting.
WASHINGTON, March 10 /PRNewswire-USNewswire/ -- Allan Coukell, director of the Pew Prescription Project, issued the following statement today, commenting on a hearing at the U.S.